Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma

Pathology and Oncology Research

Volumn 18, Issue 4, 2012, Pages 911-916

  Zhang, Yang ^a   Deng, Zhan Sheng ^a   Liao, Ming Mei ^a   Wang, Ning ^a   Zhang, Xiao Qing ^a   Yu, Hai Yang ^a   Zhang, Yang De ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Clinicopathology; Disease free survival; Hepatocellular carcinoma; Overall survival; Prognosis; Tumor associated glycoprotein 72

Indexed keywords

GLYCOPROTEIN; TAG 72 ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868501559     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9521-0     Document Type: Article

References (16)

1. Zhang MF, Zhang ZY, Fu J, Yang YF, Yun JP (2009) Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med 7:110
2. Teo EK, Fock KM (2001) Hepatocellular carcinoma: an Asian perspective. Dig Dis 19:263-268
3. Leoni S, Piscaglia F, Righini R, Bolondi L (2006) Management of small hepatocellular carcinoma. Acta Gastroenterol Belg 69:230-235
4. Jin B, Wang X, Jin Y et al (2009) Detection of serum gastric cancer-associated MG7-Ag from gastric cancer patients using a sensitive and convenient ELISA method. Cancer Invest 27:227-233
5. Molina R, Auge JM, Escudero JM et al (2008) Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 29:371-380
6. Chen L, Wang Y, Liu X et al (2008) A new TAG-72 cancer marker peptide identified by phage display. Cancer Lett 272:122-132
7. Kim SJ, Hong HJ (2007) Guided selection of human antibody light chains against TAG-72 using a phage display chain shuffling approach. J Microbiol 45:572-577
8. Chauhan SC, Vinayek N, Maher DM et al (2007) Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibodyguided therapy. J Histochem Cytochem 55:867-875
9. Mohsin H, Jia F, Sivaguru G, Hudson MJ et al (2006) Radiolanthanide- labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu. Bioconjug Chem 17:485-492
10. Santos-Juanes J, Bernaldo de Quirós JF, Galache Osuna C et al (2004) Apocrine carcinoma, adenopathies, and raised TAG-72 serum tumor marker. Dermatol Surg 30:566-569
11. Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW (2010) Improved efficacy of alpha-particletargeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer 116:1059-1066
12. Zou P, Xu S, Povoski SP et al (2009) Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm 6:428-440
13. Oei AL, Sweep FC, Thomas CM, Boerman OC, Massuger LF (2008) The use of monoclonal antibodies for the treatment of epithelial ovarian cancer. Int J Oncol 32:1145-1157
14. Ponnusamy MP, Venkatraman G, Singh AP et al (2007) Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett 251:247-257
15. Ouyang M, Wu W, Zou Y, Zhou J, Wang Z, Wan X (2010) Immunoreactivity and prognostic value of tumor-associated glycoprotein 72 in primary gallbladder carcinoma. Surg Oncol 19:82-87
16. Graves SS, Dearstyne E, Lin Y et al (2003) Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 9:3712-3721